Charles River Laboratories International has had a sharp re-rating over the past year, which puts a spotlight on whether the current share price lines up with the cash the business is expected to generate. With investors reacting to both strong recent returns and fresh corporate developments, the central question is how today’s valuation stacks up against its underlying cash flows.
- The stock has delivered a 94.6% return over the past year. This raises the stakes on whether recent optimism is fully supported by the company’s cash flow profile.
- Management has outlined a Pathway to Purpose plan and new initiatives around operational excellence and scientific leadership. These developments can influence future cash generation through potential changes in revenue growth, margins and reinvestment needs.
- What if you looked at Charles River Laboratories International through its sales instead? See what Charles River Laboratories International's 3.9x P/S says about the price.
The issue now is whether Charles River Laboratories International's current share price is justified by the intrinsic value suggested by its cash flows.
If you want a wider lens on this kind of valuation question, you can compare Charles River Laboratories International with other businesses in our 35 high quality undervalued stocks for a cash flow focused cross-check.
Where Does Charles River Laboratories International Sit on Cash Flow?
The Discounted Cash Flow (DCF) model here projects what Charles River Laboratories International might produce in future free cash and then compares that stream to today’s $326.29 share price. Latest twelve month free cash flow sits at about $403 million, and the projections imply growing free cash generation over the next decade rather than a shrinking profile.
The DCF points to an estimated intrinsic value that is broadly in line with where the stock trades, so the current price already reflects those rising cash flow expectations. Because third quarter 2026 results came with raised guidance and a fresh Pathway to Purpose plan, the market appears to be treating that stronger outlook as largely consistent with what the cash flow model already assumes. Find out what Charles River Laboratories International could be worth using our Discounted Cash Flow (DCF) estimate.
The Charles River Laboratories International Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Charles River Laboratories International pick up where this valuation puzzle leaves off by spelling out what paths for growth, profitability and earnings would need to hold for the shares to be worth materially more or materially less than today’s price on the Community page. Each storyline ties its numbers to a specific view on how Charles River Laboratories International's growth, margins and risks might evolve, which gives you something concrete to revisit as fresh information arrives.
Community views on Charles River Laboratories International are split between one group that sees more upside in the plan and another that treats the stock as roughly fairly valued.
Bull case: 16% undervalued
"Refocused Manufacturing Solutions, which already reported a 37.8% operating margin in 2Q26 and is targeted for organic growth of 7% to 9% with margins above 40% by 2030, gives Charles River Laboratories International room for mix driven operating margin expansion and more recurring cash flows from embedded QC testing…"
Discover why this Narrative puts Charles River Laboratories International at 16% undervalued.
Bear case: roughly fairly valued
"The availability of non-human primates has become one of the hidden bottlenecks in modern biomedical research…"
Explore why this Narrative puts Charles River Laboratories International at roughly fairly valued.
One more piece of the Charles River Laboratories International story to check
Before you move on from Charles River Laboratories International, it is worth knowing that internal checks have picked up specific risk flags that could matter for anyone focusing only on valuation. Take a closer look at 3 warning signs before settling on a valuation.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com